The question every researcher in this space has to wrestle with: is that dose differential actually justified by the bioavailability differences, or is it marketing inertia from vendors trying to differentiate products
Regulatory Support and Framework Development The FDA's December 2023 final guidance on decentralized clinical trials the first comprehensive federal-level framework on the topic in the United States codified acceptable uses of remote monitoring, telehealth investigator visits, and direct-to-patient drug shipment within regulated clinical studies
It belongs to a class of drugs called Non-Steroidal Anti-Inflammatory Drugs, or NSAIDs
For payers and decision-makers, oral peptides present both opportunity and uncertainty
Shi J, Willemze A, Janssen GM, van Veelen PA, Drijfhout JW, Cerami A, et al